A Phase 1/2 interventional study of AZD0120 in Relapsed/Refractory Multiple Myeloma, sponsored by AstraZeneca. Recruiting at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma — 7 open to participants now, 7 under way, 3 of them phase 3. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F · Multiple Myeloma.
Among the 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma, this one is the 4th largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 1/2, and was the 5th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →7 of the 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, Brazil and 15 more countries
Ages 18–130
AstraZeneca · Sites in United States, Australia, Brazil and 12 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Brazil and 12 more countries
Ages 18+
AstraZeneca · Sites in United States
Ages 18+
Gracell Biotechnologies (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 3
First in 2020; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 232 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 40 across the 11 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 3 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
16 studies in Multiple Myeloma by AstraZeneca: 8 open now, 8 under way, 3 of them phase 3. Of 8 finished, 4 (50%) have results posted.
Among the 16 studies in Multiple Myeloma by AstraZeneca, this one is the 4th largest by planned enrollment, is one of 3 that started in 2023, is one of 7 in phase 1/2, and was the 9th registered.
AstraZeneca’s Multiple Myeloma studies by the year they started, since 2008.
1 of the studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850234AstraZenecaAZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma, from their registry updates:
Among AstraZeneca’s 16 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Phase 1b aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect, and immunogenicity in subjects with relapsed/refractory multiple myeloma and determine the recommended Phase 2 dose of AZD0120.
Phase II aims to evaluate the efficacy of AZD0120, and to further characterize the safety, pharmacodynamic effects, immunogenicity, and changes in health-related quality of life parameters in subjects with relapsed/refractory multiple myeloma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria :
Any other significant medical conditions such as:
Other protocol-defined Inclusion/Exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD0120 will be administered by infusion
Biological: AZD0120
AZD0120 is a BCMA/CD19 dual CAR T product under investigation for the treatment of participants with RRMM.
Phase 1b: Adverse Events (AEs)
The incidence and severity of AEs.
Time frame: Through study completion, a minimum of 2 years.
Phase 1b: Dose-Limiting Toxicities (DLTs)
The DLT evaluation period is defined as the first 28 days after infusion.
Time frame: 28 days
Phase 2: Objective Response Rate (ORR)
Defined as the proportion of participants who achieved partial response (PR) or better by the International Myeloma Working Group (IMWG) response criteria.
Time frame: Through study completion, a minimum of 2 years.
Phase 1b and 2: Complete response rate (CRR)
Defined as the proportion of participants who achieved complete response (CR) or better per International Myeloma Working Group (IMWG) criteria.
Time frame: Through study completion, a minimum of 2 years.
Phase 1b and 2: Time to response (TTR)
Defined as the time between date of apheresis and the first efficacy evaluation that the participant has met all criteria for partial response (PR) or better.
Time frame: Through study completion, a minimum of 2 years.
Phase 1b: Objective Response Rate (ORR)
Defined as the proportion of participants who achieved PR or better by IMWG response criteria.
Time frame: Through study completion, a minimum of 2 years.
Phase 1b and 2: Minimal Residual Disease (MRD) negative Complete Response (CR) rate
Defined as the proportion of participants who achieve CR or better response with MRD negativity per IMWG criteria.
Time frame: Through study completion, a minimum of 2 years.
Phase 1b and 2: Minimal Residual Disease (MRD) negative Complete Response (CR) rate at 12 months
Defined as the proportion of participants who achieve CR or better response with MRD negativity per IMWG criteria at 12 months.
Time frame: 12 months
Phase 1b and 2: Duration of response (DOR)
Defined among responders as the time from the date of initial documentation of an objective response (overall response of PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.
Time frame: Through study completion, a minimum of 2 years.
Phase 1b and 2: Progression-free survival (PFS)
Defined as the time from the date of apheresis to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.
Time frame: Through study completion, a minimum of 2 years.
Phase 1b and 2: Overall survival (OS)
Defined as the time from the date of apheresis to the date of the subject's death.
Time frame: Through study completion, a minimum of 2 years.
Phase 2: Adverse Events (AEs)
Further characterization of the safety of AZD0120 by measuring the incidence and severity of AEs.
Time frame: Through study completion, a minimum of 2 years.
Ph1b and 2: Pharmacokinetics - AUC
Area under the concentration time-curve of AZD0120 CAR transgene copies.
Time frame: Through study completion, a minimum of 2 years.
Ph1b and 2: Pharmacokinetics - Clast
Last quantifiable AZD0120 CAR transgene copies.
Time frame: Through study completion, a minimum of 2 years.
Ph1b and 2: Pharmacokinetics - Cmax
Maximum AZD0120 CAR transgene copies.
Time frame: Through study completion, a minimum of 2 years.
Ph1b and 2: Pharmacokinetics - Tlast
Time to last quantifiable AZD0120 CAR transgene copies.
Time frame: Through study completion, a minimum of 2 years.
Ph1b and 2: Pharmacokinetics - Tmax
Time to reach maximum AZD0120 CAR transgene copies.
Time frame: Through study completion, a minimum of 2 years
Ph1b and 2: Humoral Immunogenicity
Prevalence and incidence of anti-drug antibodies (ADAs) against AZD0120 and the impact on PK, efficacy, and safety, as data allow.
Time frame: Through study completion, a minimum of 2 years.
Phase 2: Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) IL355 Bone Pain and Health-Related Quality of Life Scale Scores
Change from baseline in patient-reported bone pain and health-related quality of life, as assessed using the European Organization for Research and Treatment of Cancer Item Library 355 (EORTC IL355), including the QL2 scale.
Time frame: Through study completion, a minimum of 2 years.
Phase 2: Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) IL356 Physical Function and Fatigue Subscale Scores
Changes from baseline in patient-reported physical function and fatigue, as assessed using the European Organization for Research and Treatment of Cancer Item Library 356 (EORTC IL356).
Time frame: Through study completion, a minimum of 2 years.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Oct 2027, 50 months after the start.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 50 months is below that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F